Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia.

Abstract

Prazosin HCl was administered in dosages of 1.5-4.5 mg/day for 4 weeks to 40 patients suffering from dysuria accompanying prostatic hyperplasia. Significant reductions were observed in the mean frequency of night-time and 24-hour urination. Additionally, significant improvements were recorded for the time for start of urination, time from start to finish of urination and related variables. The improvements correlated with dosage levels. Objective variables measured by urine flow rates also exhibited significant improvement. A statistically significant decrease in systolic without a decline in diastolic blood pressure was observed. Slight dizziness was observed in 1 patient and elevated laboratory test values in another, but neither warranted discontinuation of the medication; however, 1 patient did have two doses of medication held. Overall, the drug was judged beneficial to some degree in 95% of the patients.

• Authors: H Aoki, M Ohninata, T Tsuzuki, M Ohhori, Y Shiraiwa, O Yamaguchi, M Kobayashi, T Yokota, S Numazato, S Sakuma
• Journal: Urologia internationalis (Urol Int) Vol. 45 Suppl 1 Pg. 18-25 ( 1990) ISSN: 0042-1138 [Print] Switzerland
• PMID: 1690476 (Publication Type: Journal Article)

Chemical References

• Prazosin

Topics

• Aged
• Aged, 80 and over
• Dose-Response Relationship, Drug
• Humans
• Male
• Middle Aged
• Prazosin (therapeutic use)
• Prostatic Hyperplasia (complications, drug therapy)
• Urethral Obstruction (drug therapy, etiology)
• Urination Disorders (drug therapy, etiology)
• Urodynamics (drug effects)